Journal for Immunotherapy of Cancer 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity
ConclusionsOur study highlights the importance of serum choice in the generation of CAR T cells for clinical use. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: research
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC
ConclusionOur pilot MRE data suggests early change in tumor stiffness may be an indicator of immunotherapy response in patients with advanced HCC. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 27, 2019 Category: Cancer & Oncology Source Type: research
IL-17 inhibits CXCL9/10-mediated recruitment of CD8 + cytotoxic T cells and regulatory T cells to colorectal tumors
ConclusionIL-17 signals to colorectal tumor cells and inhibits their production of CXCL9/10 chemokines. By doing so, IL-17 inhibits the infiltration of CD8+ CTLs and Tregs to CRC, thus promoting CRC development. Cancer immunotherapy may be benefited by the use of anti-IL-17 agents as adjuvant therapies, which serve to block both IL-17-mediated tumor promotion and T cell exclusion. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 26, 2019 Category: Cancer & Oncology Source Type: research
Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
ConclusionsGDNPs can alter M2 polarization both in vitro and in vivo, which contributes to an antitumor response. The polarization of macrophages induced by GDNPs is largely dependent on TLR4 and MyD88 signalling. GDNPs as an immunomodulator participate in mammalian immune response and may represent a new class of nano-drugs in cancer immunotherapy. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 26, 2019 Category: Cancer & Oncology Source Type: research
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
AbstractThe immunologic landscape of the host and tumor play key roles in determining how patients will benefit from immunotherapy, and a better understanding of these factors could help inform how well a tumor responds to treatment. Recent advances in immunotherapy and in our understanding of the immune system have revolutionized the treatment landscape for many advanced cancers. Notably, the use of immune checkpoint inhibitors has demonstrated durable responses in various malignancies. However, the response to such treatments is variable and currently unpredictable, the availability of predictive biomarkers is limited, a...
Source: Journal for Immunotherapy of Cancer - November 26, 2019 Category: Cancer & Oncology Source Type: research
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma
AbstractTumors that lack pre-existing immune infiltration respond poorly to T cell checkpoint blockade immunotherapy. These cancers often surround themselves with high densities of suppressive myeloid stroma while excluding immunostimulatory dendritic cells. Tumor-resident myeloid cells and selected lymphocyte populations retain expression of Toll-like Receptors (TLR) that sense common features of pathogens and activate innate immunity in response. We explored whether agonists of TLR9 could augment innate immunity to promote tumor regression alone or in combination with T cell checkpoint blockade. In the setting of the imm...
Source: Journal for Immunotherapy of Cancer - November 25, 2019 Category: Cancer & Oncology Source Type: research
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
ConclusionSarcosine increases the migration of murine and human DCs via the CXC chemokine pathway. This platform can be utilized to improve existing DC vaccine strategies. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
ConclusionsBoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
ConclusionsHBV reactivation occurs in a subset of HBsAg-positive cancer patients undergoing anti-PD-1 or anti-PD-L1 immunotherapy. Regular monitoring of HBV DNA and antiviral prophylaxis are advised to prevent this potentially fatal complication. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
ConclusionsThese findings demonstrate a similar exposure-safety profile of atezolizumab in pediatric and young adult patients, supportive of weight-based dosing in pediatric patients.Trial registrationNCT02541604. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 high B lymphocytes
ConclusionsBTLA detected in cancerous tissues can predict poor outcome of EOC patients. Inhibition of BTLA combined with chemotherapy can elevate immune activation and generate potent anti-tumor effects. Thus, the combination of chemotherapy and anti-BTLA antibody may hold potential clinical application for the treatment of EOC patients.Trial registrationThe Trial Registration Number wasNCT00854399. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
ConclusionsMG is a life-threatening adverse event of acute onset and rapid progression after ICI initiation. Early use of IVIG or PLEX, regardless of initial symptoms severity, may lead to better outcomes than steroids alone. Our data suggest the need to reassess the current recommendations for management of ICI-related MG until prospective longitudinal studies are conducted to establish the ideal management approach for these patients. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
ConclusionsThis study is the first to achieve selective depletion of specific M2-like macrophage subsets, opening the possibility of eradicating cancer-supporting TAMs whilst sparing those with anti-tumour potential. Targeted TAM depletion with T cell engager-armed EnAd offers a powerful therapeutic approach combining direct cancer cell cytotoxicity with reversal of immune suppression. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
ConclusionsOur study provides the first report of the severe, early reactivation of an inactive HBsAg carrier after CAR T cell therapy in DLBCL.Trial registrationChiCTR-OPN-16008526. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature
ConclusionThe confinement within the radiation field and the latency of appearance are suggestive of delayed radiation myelopathy. Nevertheless, the relatively low dose of radiation received and the full recovery after pembrolizumab discontinuation and steroid therapy plead for the contribution of both radiotherapy and immunotherapy in the causality of this complication, as an enhanced inflammatory reaction on a focal post-radiation chronic inflammatory state. In the three previously described cases of myelopathy occurring after radiotherapy and immunotherapy, a complete recovery had not been obtained and the immunotherapy...
Source: Journal for Immunotherapy of Cancer - November 20, 2019 Category: Cancer & Oncology Source Type: research
